Global cancer statistics, CA Cancer J Clin, vol.65, p.25651787, 2012. ,
SEER data submission, posted to the SEER web site, National Cancer Institute. Bethesda, MD, 1975. ,
Clinical Implications of Genomic Discoveries in Lung Cancer, N Engl J Med, vol.374, pp.1864-1873, 2016. ,
Non-small-cell lung cancers: a heterogeneous set of diseases, Nat Rev Cancer, vol.14, p.25056707, 2014. ,
Circulating tumor DNA as a liquid biopsy for cancer, Clin Chem, vol.61, pp.112-123, 2015. ,
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle, Ann Oncol, vol.25, pp.1729-1735, 2014. ,
Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA, Nat Commun, vol.6, p.8258, 2015. ,
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med, vol.368, pp.1199-1209, 2013. ,
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer, Nat Commun, vol.6, p.8760, 2015. ,
Rapid Clearance of Fetal DNA from Maternal Plasma, Am J Hum Gen, vol.64, pp.218-224, 1999. ,
Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, pp.985-990, 2008. ,
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis, Cancer Epidemiol Biomarkers Prev, vol.24, pp.206-212, 2015. ,
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, pp.1345-1353, 2014. ,
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial, JAMA Oncol, vol.1, pp.149-157, 2015. ,
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA, Clin Chem, vol.61, pp.1191-1196, 2015. ,
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer, JAMA Oncol, pp.1-14, 2016. ,
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, Clin Cancer Res, vol.20, p.24429876, 2014. ,
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, p.25939061, 2015. ,
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291, Lung Cancer, vol.90, pp.509-515, 2015. ,
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance, Sci Rep, vol.6, p.20913, 2016. ,
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168071
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, p.23938455, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci U S A, vol.102, pp.16368-16373, 2005. ,
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA, Sci Transl Med, vol.4, p.22649089, 2012. ,
Detection and quantification of rare mutations with massively parallel sequencing, Proc Natl Acad Sci U S A, vol.108, p.21586637, 2011. ,
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, p.25851626, 2015. ,
Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA, Clin Chem, vol.62, p.27624137, 2016. ,
Baseline tumour measurements predict survival in advanced non-small cell lung cancer, Br J Cancer, vol.109, pp.1476-1481, 2013. ,
Determining lower limits of detection of digital PCR assays for cancer-related gene mutations, Biomol Detect Quantif, vol.1, pp.8-22, 2014. ,
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, vol.20, p.20644199, 2010. ,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1426, 2016. ,
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition, Cancer Discov, vol.3, pp.350-362, 2013. ,
Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics, Chronic Dis Transl Med, vol.1, pp.175-186, 2015. ,
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, p.24705333, 2014. ,
Cell-Free Plasma DNA as a Predictor of Outcome in Severe Sepsis and Septic Shock, Clin Chem, vol.54, pp.1000-1007, 2008. ,
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy, Clin Cancer Res, vol.21, pp.3196-3203, 2015. ,
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02), Oncotarget, vol.7, pp.6984-6993, 2016. ,